ZURICH (Reuters) – Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.
The IPO implied a base offer size of around 75 million francs, rising to about 80 million francs ($88.53 million) if the over-allotment option is fully exercised, the firm said.
Book-building is expected to end on Feb. 5 and the final offer size should be published the next day, with the first day of trading earmarked for Feb. 7, it said.
The company, which focuses on research and development of antibacterial products, said last week about half of the stock would be subscribed by existing shareholders.
Among them, Britain’s GSK has committed to investing 3.5 million francs in the IPO, BioVersys said.
($1 = 0.9036 Swiss francs)
(Writing by Dave Graham; Editing by Ludwig Burger)
